| Document |
Document Title |
|
WO/2023/051759A1 |
Disclosed are a tricyclic compound and a preparation method therefor. Specifically, a tricyclic compound represented by formula I-d, a preparation method therefor, and a use thereof for preventing and/or treating tumors or cancer are dis...
|
|
WO/2023/056039A1 |
Described herein are azetidine and pyrrolidine PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
|
|
WO/2023/052638A1 |
The invention relates to compounds of formula I : (I) More particularly the invention relates to such compounds as inhibitors of 3CLpro protease. Accordingly, invention relates to a pharmaceutical composition comprising said compounds, a...
|
|
WO/2023/052363A1 |
The present invention encompasses compounds of formula (I), wherein the groups A, R1, R3 and R4 have the meanings given in the claims and specification, proteolysis targeting chimera (PROTACs) comprising such compounds of formula (I), th...
|
|
WO/2023/056421A1 |
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or dis...
|
|
WO/2023/051490A1 |
Provided in the present invention is a pharmaceutical composition of a small molecular GLP-1R receptor agonist suitable for oral administration. More specifically, the present invention relates to a pharmaceutical composition containing ...
|
|
WO/2023/051302A1 |
A heterocyclic compound having cyclin-dependent kinase inhibitory activity, a preparation method therefor and a medical use thereof. Specifically, the present invention relates to a compound as shown in general formula (I), a preparation...
|
|
WO/2023/053039A1 |
Provided herein are novel compounds having an inhibitory effect on the activation of a STING pathway. The provided compounds are 1,2-diaminobenzimidazole derivatives represented by a compound formula (I) or a pharmaceutically acceptable ...
|
|
WO/2023/053015A1 |
The present invention provides compounds of formula (I) and/or salts thereof and/or stereoisomers thereof and/or enantiomers thereof and/or racemates thereof and/or diastereomers thereof and/or biologically active metabolites thereof and...
|
|
WO/2023/051495A1 |
The present invention relates to isoquinolinone and quinazolinone compounds as represented by formula (I) or (II), a pharmaceutical composition containing the compounds, and the use of the compounds and the pharmaceutical composition the...
|
|
WO/2023/054367A1 |
Provided is a composition for forming an electrode, said composition being suitable for use as a material for forming for batteries such as lithium ion batteries and being capable of improving the rate characteristics of a battery. The c...
|
|
WO/2023/053009A1 |
The present invention relates to pyridines and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.
|
|
WO/2023/051812A1 |
Provided are a compound represented by formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate, and eutectic or deuterated compound thereof, or a pharmaceutical composition comprising same, and a use thereof as a PARP-1 in...
|
|
WO/2023/056405A1 |
Provided herein are solid forms comprising a compound of formula (I), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing a compound of...
|
|
WO/2023/055827A1 |
Described herein are compounds that are parathyroid hormone (PTH) receptor modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the tr...
|
|
WO/2023/051628A1 |
Disclosed are SOS1 inhibitors having a pyrido six-membered ring structure, and a preparation method therefor and the use thereof. The SOS1 inhibitors have a structural formula as represented by formula (I), have an SOS1 inhibitor activit...
|
|
WO/2023/051606A1 |
Provided are the medical use of an SHP2 inhibitor in combination with EGFR-TKI in the treatment and prevention of tumor diseases, and the use of the SHP2 inhibitor in the preparation of a drug for treating EGFR-TKI-resistant tumor diseas...
|
|
WO/2023/052593A1 |
The invention concerns compounds having antiviral activity, in particular having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising th...
|
|
WO/2023/056463A1 |
Disclosed are methods and compositions for treating CTNNB1 syndrome. The disclosed methods and compositions may utilize or comprise a glycogen synthase kinase 3 (GSK3) inhibitor, or a pharmaceutically acceptable salt thereof. The GSK3 in...
|
|
WO/2023/049364A1 |
The present disclosure is directed to compounds of formula (I):; wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates ...
|
|
WO/2023/045942A1 |
Disclosed is a 1,2-dihydro-3H-pyrazole[3,4-d]pyrimidin-3-one compound serving as a Wee-1 inhibitor. Specifically, the present invention relates to a compound as shown in general formula (1) and a preparation method therefor, as well as a...
|
|
WO/2023/049885A1 |
The present application discloses compounds having the following formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and X are defined in the specification, as well as methods of making and using the compou...
|
|
WO/2023/048152A1 |
The present invention provides: a compound having a serotonin 5-HT2A receptor antagonist and/or inverse agonist activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same. A compound represen...
|
|
WO/2023/045608A1 |
Disclosed in the present invention are a new crystal form of rimegepant and a preparation method therefor. According to crystal form APTI-II of rimegepant, an X-ray powder diffraction pattern represented by 2θ angles using Cu-Kα radiat...
|
|
WO/2023/046877A1 |
The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including ...
|
|
WO/2023/046198A1 |
The present invention relates to sulfa ketone compounds, a preparation method therefor, and a medical use thereof. In particular, the present invention relates to a sulfa ketone compound represented by general formula (I), a preparation ...
|
|
WO/2023/045360A1 |
The present invention relates to the technical field of drug synthesis. Disclosed are a crystal form of a macrocyclic compound, and a preparation method therefor and the use thereof. The macrocyclic compound is (6R, 16R)-9-fluoro-16-meth...
|
|
WO/2023/046698A1 |
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therape...
|
|
WO/2023/046806A1 |
The present invention relates to compounds of formula (I), (I), wherein R1 to R3, A, M, W and Q are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using th...
|
|
WO/2023/046214A1 |
The invention belongs to the field of pharmacology, and particularly relates to an inhibitor of a receptor-interacting protein kinase 1, and a preparation method and use therefor. Specifically provided is a spiro compound having a struct...
|
|
WO/2023/046158A1 |
Provided are an azaquinolinone compound, an isomer, a solvate, a deuterated derivative or a pharmaceutically acceptable salt of the compound. In addition, also provided are a drug using the compound, the isomer, the solvate, the deuterat...
|
|
WO/2023/049691A1 |
Compounds of Formula (I) and pharmaceutically active salts thereof are provided, where the variables in Formula (I) are described herein. Such compounds and salts are CDK7 inhibitors that are useful for treating conditions characterized ...
|
|
WO/2023/046182A1 |
Provided is an application of a pyrido[1,2-a]pyrimidone compound, and specifically involved is an application of a substance X in preparation of a drug. The substance X is a compound represented by formula I, a pharmaceutically acceptabl...
|
|
WO/2023/046034A1 |
A nitrogen-containing heterocyclic compound, a preparation method therefor, an intermediate thereof, and an application thereof. A nitrogen-containing heterocyclic compounds as shown in formula II-a, II-b, I-c, or I-d, a preparation meth...
|
|
WO/2023/049270A1 |
Compounds having activity as inhibitors of Tyro3 are provided. The compounds have Structure (I): or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof, wherein X, Y, R1, R2a, R3a, R3b, and n are as defined her...
|
|
WO/2022/170974A9 |
Provided are a compound of formula (I) that inhibit the activity of PARP7, a stereoisomer thereof, a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, an intermediate to prepare the compound, a process to prep...
|
|
WO/2023/045960A1 |
A pyridine derivative and use thereof. The compound has an obvious inhibitory effect on the activity of KRAS and PI3K proteins, can be used as a KRAS and/or PI3K protein inhibitor, and can be used for preparing a drug for treatment of di...
|
|
WO/2023/049199A1 |
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including autoimmune diseases, inflammatory conditions a...
|
|
WO/2023/049697A1 |
Claimed are compounds of Formula la, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or diso...
|
|
WO/2023/041066A1 |
Provided are a pyrimidine-containing dihydropyrazolone derivative, a prodrug thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a preparation method therefor and an application thereof. The compound can i...
|
|
WO/2023/043040A1 |
The present invention provides a novel compound for a light-emitting device, and an organic light-emitting device comprising same.
|
|
WO/2023/040818A1 |
Disclosed are a RIPK1 inhibitor that inhibits programmed cell necrosis and a preparation method therefor. The disclosed RIK1 inhibitor is represented by general formula I, where X1, X2, X3, X4, X5, Z1, Z2, Z3, L1, L2, L3, R, R1, ring D a...
|
|
WO/2023/041004A1 |
The present disclosure relates to a substituted 1,4-dihydro-1,6-naphthyridine amide and a use thereof. Specifically, a compound represented by formula I or a pharmaceutically acceptable salt thereof is provided, where R1, R3-R11, Z1 and ...
|
|
WO/2023/043938A1 |
Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a sulfamide RNR inhibitor disclosed herein.
|
|
WO/2023/042879A1 |
The present invention provides: a compound having coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same. Provided is a compound represented by formula...
|
|
WO/2023/041049A1 |
Provided are a class of heterocyclic compounds as an SOS1 inhibitor, specifically disclosed are a compound represented by formula (I), a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound and t...
|
|
WO/2023/043836A1 |
Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, dis...
|
|
WO/2023/039828A1 |
Relates to fused ring compounds, and pharmaceutical compositions including the same, inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases, especially FGFR4-associated diseases, such as cancer.
|
|
WO/2023/039662A1 |
The present disclosure provides compounds according to Formulas I and II: where R1 to R11 independently denote: H; D; a halogen; an optionally substituted straight chain or branched alkyl group; an optionally substituted alkenyl group; a...
|
|
WO/2023/039682A1 |
LSD derivative compounds and polymorphs thereof, methods for their synthesis, compositions and treatment of diseases and disorders are described herein, the compounds having the structure of Formula (I):, including pharmaceutically accep...
|
